Your browser doesn't support javascript.
loading
Camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and hepatic artery infusion chemotherapy for hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (TRIPLET): a phase II study.
Zhang, Tian-Qi; Geng, Zhi-Jun; Zuo, Meng-Xuan; Li, Ji-Bin; Huang, Jin-Hua; Huang, Zi-Lin; Wu, Pei-Hong; Gu, Yang-Kui.
Afiliação
  • Zhang TQ; Department of Minimally Invasive Interventional Therapy, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China.
  • Geng ZJ; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, P. R. China.
  • Zuo MX; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, P. R. China.
  • Li JB; Department of Radiology, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China.
  • Huang JH; Department of Minimally Invasive Interventional Therapy, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China.
  • Huang ZL; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, P. R. China.
  • Wu PH; Department of Clinical Research, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China.
  • Gu YK; Department of Minimally Invasive Interventional Therapy, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China.
Signal Transduct Target Ther ; 8(1): 413, 2023 10 27.
Article em En | MEDLINE | ID: mdl-37884523
ABSTRACT
Hepatic arterial infusion chemotherapy (HAIC) using a combination of oxaliplatin, fluorouracil, and leucovorin (FOLFOX) has shown promise for hepatocellular carcinoma (HCC) patients classified under Barcelona Clinic Liver Cancer (BCLC) stage C. In China, the combined therapy of camrelizumab and apatinib is now an approved first-line approach for inoperable HCC. This study (NCT04191889) evaluated the benefit of combining camrelizumab and apatinib with HAIC-FOLFOX for HCC patients in BCLC stage C. Eligible patients were given a maximum of six cycles of HAIC-FOLFOX, along with camrelizumab and apatinib, until either disease progression or intolerable toxicities emerged. The primary outcome measured was the objective response rate (ORR) based on the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Thirty-five patients were enrolled. Based on RECIST v1.1 criteria, the confirmed ORR stood at 77.1% (95% CI 59.9% to 89.6%), with a disease control rate of 97.1% (95% CI 85.1% to 99.9%). The median progression-free survival was 10.38 months (95% CI 7.79 to 12.45). Patient quality of life had a transient deterioration within four cycles of treatment, and generally recovered thereafter. The most frequent grade ≥3 or above treatment-related adverse events included reduced lymphocyte count (37.1%) and diminished neutrophil count (34.3%). The combination of camrelizumab, apatinib, and HAIC demonstrated encouraging results and manageable safety concerns for HCC at BCLC stage C.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Neoplasias Hepáticas Limite: Humans Idioma: En Revista: Signal Transduct Target Ther Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Neoplasias Hepáticas Limite: Humans Idioma: En Revista: Signal Transduct Target Ther Ano de publicação: 2023 Tipo de documento: Article